Chief Financial Officer
He previously worked for over 15 years at the AIM and Nasdaq listed biotechnology company, Summit Therapeutics. He held a variety of scientific and business roles as the company matured from being a University of Oxford spin-out into a global, late-stage clinical development organisation; most recently Richard held the position of Vice President of Corporate Affairs and Investor Relations. During his time with Summit, Richard gained strong cross border experience of the UK and US capital markets, investor relations, financial reporting, corporate development and strategy, and corporate governance for AIM and Nasdsq.
He holds a PhD in organic chemistry and was a Post Doctoral Research Associate at the University of Oxford prior to moving into the biotechnology industry.